These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30652379)

  • 1. Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer.
    Cabezas-Camarero S; García-Barberán V; Sáiz-Pardo Sanz M; Cabrera-Martín MN; Gimeno-Hernández J; Pérez-Segura P
    Head Neck; 2019 Jun; 41(6):E86-E92. PubMed ID: 30652379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
    Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
    Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
    Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Li L; Ferris RL
    Oncologist; 2018 Sep; 23(9):1079-1082. PubMed ID: 29866947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
    Wu L; Yu Y; Zhou J; Wang X; Li J; Wang Y
    Immunotherapy; 2020 Sep; 12(13):957-964. PubMed ID: 32686549
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
    Kokkali S; Ntokou A; Drizou M; Perdikari K; Makaronis P; Katsarou E; Koufopoulos N; Tzovaras A; Ardavanis A
    Oral Oncol; 2020 Feb; 101():104359. PubMed ID: 31300270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
    Takemoto K; Miyahara N; Chikuie N; Hamamoto T; Ishino T; Ueda T; Takeno S
    Auris Nasus Larynx; 2019 Oct; 46(5):813-817. PubMed ID: 30442438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
    Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
    Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Pérez-Segura P
    Anticancer Drugs; 2019 Feb; 30(2):149-152. PubMed ID: 30339560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
    Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
    Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
    Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV
    J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab.
    Ueda T; Chikuie N; Takumida M; Furuie H; Kono T; Taruya T; Hamamoto T; Hattori M; Ishino T; Takeno S
    Acta Otolaryngol; 2020 Feb; 140(2):181-187. PubMed ID: 31825711
    [No Abstract]   [Full Text] [Related]  

  • 20. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.